RecruitingNCT07155252
Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening
Sponsor
Yale University
Enrollment
60 participants
Start Date
Aug 26, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical type 1 diabetes (T1D) (carriers of at least one islet autoantibody) or with new onset Stage 3 T1D within 100 days from the diagnosis.
Eligibility
Min Age: 8 YearsMax Age: 45 Years
Inclusion Criteria7
- Body weight ≥43 kg
- Presence of at least one islet autoantibody and/or≥ diagnosis of clinical T1D within 100 days.
- Documentation of the presence at least 1 islet autoantibody
- If participants meet ADA diagnostic criteria for Stage 3 type 1 diabetes, they will be eligible if the enrollment occurs within 100 days from the diagnosis and are at least 12 years old.
- Participants must be in good general health without other acute (e.g. infectious disease) febrile or chronic illnesses (e.g. uncontrolled asthma requiring high steroid doses, chronic arthritis) that in the judgment of the investigator could jeopardize participant safety or interfere with the study,
- Ability to give consent/assent
- Able to understand written and spoken English
Exclusion Criteria3
- Currently pregnant or becomes pregnant during the study
- Participants on sodium glucose cotransporter inhibitors (SGLTi).
- Donated blood in the past 8 weeks.
Interventions
DIAGNOSTIC_TESTGTT@Home
self-administered fingerstick based glucose tolerance test
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07155252
Related Trials
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT063246044 locations
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
NCT060148791 location
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT061987251 location
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
NCT072121791 location
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
NCT0706157411 locations